Edition:
United Kingdom

Idorsia Ltd (IDIA.S)

IDIA.S on Swiss Exchange

21.65CHF
15 Dec 2017
Change (% chg)

CHF0.25 (+1.17%)
Prev Close
CHF21.40
Open
CHF21.50
Day's High
CHF21.65
Day's Low
CHF21.20
Volume
1,161,419
Avg. Vol
339,452
52-wk High
CHF22.90
52-wk Low
CHF10.00

Chart for

About

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including... (more)

Overall

Beta: --
Market Cap(Mil.): CHF2,096.57
Shares Outstanding(Mil.): 119.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 million from J&J in latest hypertension deal

ZURICH Idorsia , the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) , will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

Idorsia to get $230 mln from J&J in latest hypertension deal

ZURICH, Dec 4 Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension.

04 Dec 2017

BRIEF-Idorsia Announces Collaboration With Janssen Biotech On Aprocitentan

* IDORSIA ANNOUNCES COLLABORATION WITH JANSSEN BIOTECH ON APROCITENTAN (ACT-132577)

04 Dec 2017

BRIEF-Idorsia ‍H1 ‍US GAAP operating loss of CHF 11 million​

* ‍GUIDANCE FOR FULL YEAR 2017: NON-GAAP OPERATING EXPENSES OF CHF 180-190 MILLION​

03 Aug 2017

BRIEF-Idorsia: Act-541468 (Dora) meets primary endpoint in Phase 2

* ACT-541468 (DORA) MEETS PRIMARY ENDPOINT IN PHASE 2 PROGRAM IN ADULT AND ELDERLY PATIENTS WITH INSOMNIA

28 Jul 2017

Earnings vs. Estimates